Search the Newsreel

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap …

Tarsus (TARS) Q2 2026 Earnings Call Transcript

Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus

Janus Henderson Group Ltd. has disclosed a 6.5% beneficial ownership stake in Tarsus Pharmaceuticals, Inc., totaling 2,808,796 shares of common stock. This ownership is held through its affiliated asset managers via Managed Portfolios, where they exercise investment and voting discretion. The filing indicates shared …

Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100

Mizuho Securities analyst Graig Suvannavejh has reiterated a Buy rating for Tarsus Pharmaceuticals (TARS.US), maintaining a target price of $100. According to TipRanks data, Suvannavejh has a 52.0% success rate and a 24.3% average return over the past year. The information is provided for …

Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating

Oppenheimer has increased its price target for Tarsus Pharmaceuticals (TARS) to $100 from $97, while maintaining an "Outperform" rating on the stock. This adjustment comes amidst recent company activities including an acquisition agreement with Alkeus Pharmaceuticals and Q2 2026 earnings results. Mizuho also recently …

Tarsons Products Q1 Results: Earnings call audio uploaded

HC Wainwright Has Bearish Estimate for TARS Q3 Earnings

Tarsons Product Standalone June 2026 Net Sales at Rs 86.15 crore, up 20.86% Y-o-Y

Tarsons Products Q1 Results: Consolidated net loss widens to ₹14.44 million

Tarsons Products Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Tarsus Pharmaceuticals (TARS) Lifts XDEMVY Guidance Following Earnings But Is The Stock Already Priced In

Tarsus Pharmaceuticals (TARS) reported strong Q2 2026 revenues of $173.91 million and raised its full-year XDEMVY sales guidance, suggesting significant commercial momentum. Despite recent stock gains, Simply Wall St's analysis indicates the stock might still be 31.2% undervalued with a fair value of $94.11 …

Tarsons Products revenue rises 21% in Q1FY27, cash PAT up 18%

Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus

Tarsus Pharmaceuticals (TARS) saw its stock rise by 9.7% after reporting strong Q2 revenue of US$173.91 million and raising its full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. The company also announced the acquisition of Alkeus Pharmaceuticals, adding a late-stage asset …

Tarsus Pharmaceuticals (TARS) Stock Can Revenue Momentum Outrun Rising Costs

Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-08-06

Tarsus Pharmaceuticals, Inc. (TARS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported an EPS of -$0.43, missing estimates by $0.23, while revenue reached $173.91M, beating expectations by $4.40M and showing a 69.41% year-over-year increase. This article includes the …

Tarsons Products schedules investor meet with Emkay Global for Aug 13

Press Release: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals announced an oversubscribed private placement equity financing of $125.0 million. The financing is led by new and existing institutional investors, including Fidelity Management & Research Company LLC, RA Capital Management, and Eventide Asset Management. The proceeds are intended to fund the continued …

Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals

Latham & Watkins LLP advised Alkeus Pharmaceuticals on its acquisition by Tarsus Pharmaceuticals, Inc. The deal, announced on July 31, 2026, involves Tarsus acquiring Alkeus, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001) for Stargardt disease. A comprehensive legal team from Latham …

Tarsus to purchase Alkeus Pharmaceuticals

Tarsus Pharmaceuticals plans to acquire Alkeus Pharmaceuticals, including its late-stage investigational therapy for Stargardt disease, gildeuretinol acetate (ALK-001). The deal involves an estimated $450 million upfront consideration in cash and stock, plus potential future milestones and royalties. ALK-001 has received multiple FDA designations and …

Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported record second-quarter 2026 net product sales of $173.9 million for …

Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside

Tarsus Pharmaceuticals, Inc.'s average 12-month stock price target has been lowered slightly from $94.22 to $93.57 by 7 analysts, with individual forecasts ranging from $84 to $104 per share. Based on the August 5th closing price, this updated target suggests a potential upside of …

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) reported a Q2 loss of $0.43 per share, exceeding the Zacks Consensus Estimate of a $0.21 loss, but surpassed revenue expectations with $173.91 million. Despite consistently beating revenue estimates, the stock has underperformed the S&P 500 year-to-date, and its current Zacks …

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals announced its plan to acquire Alkeus Pharmaceuticals in a deal valued at up to $800 million. This acquisition will expand Tarsus's eye disease pipeline by adding an experimental oral therapy for a rare inherited retinal disorder for which there is currently no …

Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals

(RTTNews) - Tarsus Pharmaceuticals, Inc (TARS), a biopharmaceutical company focused on eye care, has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a retinal disease-focused biotechnology company. Alkeus' lead candidate Gildeuretinol (ALK-001), an investigational once-daily oral therapy in Phase 3 development for …

Tarsus Pharmaceuticals (TARS) boosts H1 2026 revenue and turns operating cash flow positive

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals, Inc Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus' retina pipeline with a …

Tarsus to Raise About $125M, Selling Stock at $56 a Share

Tarsus Pharmaceuticals announced an oversubscribed private placement (PIPE) expected to generate approximately $125.0 million in gross proceeds. The company will sell 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants for 133,625 shares. The financing includes participation from both existing and …

Tarsus Pharmaceuticals to report Q2 2026 financial results on August 6

Tarsus Pharmaceuticals will host a live webcast on August 6, 2026, to discuss its second-quarter financial results and provide a corporate update. The webcast, scheduled for 5:00 a.m. PT / 8:00 a.m. ET, will offer insights into the company's progress, including its FDA-approved XDEMVY® …

Tarsus Pharmaceuticals to Host Second Quarter 2026 Financial Results Webcast and Corporate Update

Tarsus Pharmaceuticals, Inc. announced it will host a live webcast on August 6, 2026, at 5:00 a.m. PT to discuss its second-quarter 2026 financial results and provide a corporate update. The company focuses on innovative treatments in eye care, dermatology, and infectious diseases, with …

The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following Sharp EPS Estimate Cuts Amid Rising Sales

Tarsus Pharmaceuticals (TARS) is facing significantly lowered consensus earnings-per-share (EPS) estimates and a low analyst ranking ahead of its June 2026 quarterly results, despite projected year-over-year revenue increases. This tension between growing sales and weakening profit expectations raises questions about the company's long-term investment …

TARS Maintained by Mizuho -- Price Target Lowered to $98.00

Mizuho has maintained an "Outperform" rating for Tarsus Pharmaceuticals (TARS) but lowered its price target to $98.00 from $100.00. While GuruFocus's GF Value suggests the stock is significantly undervalued, the company exhibits low profitability and negative insider activity, prompting caution for investors despite analyst …

Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating

Mizuho has adjusted its price target for Tarsus Pharmaceuticals (TARS) from $100 to $98, while maintaining an Outperform rating on the stock. This revision comes after the company's recent earnings report. The firm highlighted that the Q2 report showed a notable increase in Xdemvy …

Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations

Tarsus Pharmaceuticals (TARS) is heading into its quarterly report with expectations of a loss but higher revenue. Despite a 27.6% year-to-date share price decline, the company is considered 37.8% undervalued with a fair value of $94.11, based on rapid revenue expansion, anticipated profitability shifts, …